GlassScriptPhysician profile
Christopher William Ingram
NPI 1780647032
$1,317.09
in general payments reported to CMS, 2019-2025
19 companies · $171 in 2025
The $171 reported for 2025 was less than what a typical Infectious Disease provider received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $292 · 2020: $126 · 2021: $31.88 · 2022: $178 · 2023: $376 · 2024: $142 · 2025: $171.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $689.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $689.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $292.43 | 2019-2024 | |
| Viiv Healthcare Company | $237.87 | 2019-2025 | Dovato, Cabenuva, Rukobia |
| Merck Sharp & Dohme LLC | $123.01 | 2019-2025 | Dificid, Zerbaxa, Recarbrio |
| Shionogi INC | $109.10 | 2022-2025 | Fetroja |
| Insmed, INC. | $87.80 | 2019-2025 | Arikayce, Brinsupri |
| Paratek Pharmaceuticals, INC. | $65.04 | 2019-2023 | Nuzyra |
| Cumberland Pharmaceuticals, INC. | $59.45 | 2019-2023 | Vibativ |
| Janssen Biotech, INC. | $48.38 | 2019-2023 | Symtuza |
| Pfizer INC. | $43.15 | 2019-2020 | |
| Dynavax Technologies Corporation | $39.41 | 2021-2023 | Heplisav-B |
| Abbvie INC. | $38.00 | 2022-2023 | |
| Allergan, INC. | $34.82 | 2019 | |
| Melinta Therapeutics, LLC | $32.52 | 2019-2023 | Orbactiv, Kimyrsa, Vabomere |
| Mylan Pharmaceuticals INC. | $23.59 | 2020 | |
| Astellas Pharma US INC | $20.50 | 2023 | Cresemba |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Institutional INC. | $17.29 | 2019 | |
| Nabriva Therapeutics, Plc | $17.24 | 2020 | |
| Napo Pharmaceuticals INC | $15.82 | 2019 | |
| Angiodynamics, INC. | $11.67 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Ingram listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.